Computerized Model of Cost-Utility Analysis for Treatment of Age-Related Macular Degeneration
Purpose To present a computerized model assessing individualized cost utility for current treatments for neovascular age-related macular degeneration (AMD) to enhance discussion regarding treatment options. Design Case- and eye-specific cost-utility analysis using individual case scenarios. Particip...
Gespeichert in:
| Veröffentlicht in: | Ophthalmology (Rochester, Minn.) Minn.), 2008-12, Vol.115 (12), p.2192-2198 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2198 |
|---|---|
| container_issue | 12 |
| container_start_page | 2192 |
| container_title | Ophthalmology (Rochester, Minn.) |
| container_volume | 115 |
| creator | Fletcher, E.C., MRCOphth Lade, R.J., PhD, MBA Adewoyin, T., MRCOphth Chong, N.V., FRCOphth, MD |
| description | Purpose To present a computerized model assessing individualized cost utility for current treatments for neovascular age-related macular degeneration (AMD) to enhance discussion regarding treatment options. Design Case- and eye-specific cost-utility analysis using individual case scenarios. Participants Visual acuity data from published randomized controlled trials are incorporated into this analysis. Methods Computerized model (Microsoft Visual Basic 6.0 programming) to establish preference-based cost-utility analysis in association with individual cost of treatment and blindness for neovascular AMD for both the better and worst seeing eye, with extrapolation of results over a 5-year term. Main Outcome Measures Cost per quality-adjusted life-year (QALY) and cost per QALY gained for comparison of treatments for specific visual acuities. Results All treatments show an increase in utility in comparison with best supportive care (BSC) if the better-seeing eye is treated. Ranibizumab, using the Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularisation (CNV) with or without Classic CNV Secondary to AMD (PIER) regimen, is the most cost effective at $626 938 per QALY gained for treatment of the better seeing eye. To increase utility value when treating the worst seeing eye, the vision must improve to such a degree that it becomes the better seeing eye. This level of improvement is only possible if there is |
| doi_str_mv | 10.1016/j.ophtha.2008.07.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69853704</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0161642008007677</els_id><sourcerecordid>69853704</sourcerecordid><originalsourceid>FETCH-LOGICAL-c542t-73d970378e2f1ef9a6806553f1e300aad53c9ad93764565e0474581d8b5906433</originalsourceid><addsrcrecordid>eNqFkl1rFDEUhoModlv9ByJzo3cznky-b4Rl1SpUBG0vJaSZM23W2cmaZIT11zvDLgre9CoEnvdNeM4h5AWFhgKVb7ZN3N-Xe9e0ALoB1QDVj8iKCm5qrih7TFYzRmvJWzgj5zlvAUBKxp-SM6oNAyHkinzfxN1-KpjCb-yqz7HDoYp9tYm51DclDKEcqvXohkMOuepjqq4TurLDsSzY-g7rrzi4smSdnwaXqnd4hyMmV0Icn5EnvRsyPj-dF-Tmw_vrzcf66svlp836qvaCt6VWrDMKmNLY9hR746QGKQSbLwzAuU4wb1xnmJJcSIHAFReadvpWGJCcsQvy-ti7T_HnhLnYXcgeh8GNGKdspdGCKeAPgi1Q0EqaGeRH0KeYc8Le7lPYuXSwFOzi327t0b9d_FtQdvY_x16e-qfbHXb_QifhM_DqBLjs3dAnN_qQ_3ItGM5as3BvjxzO2n4FTDb7gKPHLiT0xXYxPPST_wv8EMYwv_kDD5i3cUrzWLOlNrcW7LdlV5ZVAQ2gpFLsD3ueuOA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20108769</pqid></control><display><type>article</type><title>Computerized Model of Cost-Utility Analysis for Treatment of Age-Related Macular Degeneration</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Fletcher, E.C., MRCOphth ; Lade, R.J., PhD, MBA ; Adewoyin, T., MRCOphth ; Chong, N.V., FRCOphth, MD</creator><creatorcontrib>Fletcher, E.C., MRCOphth ; Lade, R.J., PhD, MBA ; Adewoyin, T., MRCOphth ; Chong, N.V., FRCOphth, MD</creatorcontrib><description>Purpose To present a computerized model assessing individualized cost utility for current treatments for neovascular age-related macular degeneration (AMD) to enhance discussion regarding treatment options. Design Case- and eye-specific cost-utility analysis using individual case scenarios. Participants Visual acuity data from published randomized controlled trials are incorporated into this analysis. Methods Computerized model (Microsoft Visual Basic 6.0 programming) to establish preference-based cost-utility analysis in association with individual cost of treatment and blindness for neovascular AMD for both the better and worst seeing eye, with extrapolation of results over a 5-year term. Main Outcome Measures Cost per quality-adjusted life-year (QALY) and cost per QALY gained for comparison of treatments for specific visual acuities. Results All treatments show an increase in utility in comparison with best supportive care (BSC) if the better-seeing eye is treated. Ranibizumab, using the Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularisation (CNV) with or without Classic CNV Secondary to AMD (PIER) regimen, is the most cost effective at $626 938 per QALY gained for treatment of the better seeing eye. To increase utility value when treating the worst seeing eye, the vision must improve to such a degree that it becomes the better seeing eye. This level of improvement is only possible if there is <9 letters difference between the 2 eyes and treated with ranibizumab. Over 5 years, increasing influence from the cost of blindness results in increasing costs for those treatments unable to stabilize vision. Within 5 years, the cost per QALY for the BSC is greater than all treatments except monthly ranibizumab injections. Conclusions Assessment of cost of treatment incorporates both effectiveness of treatment, cost of treatment, and cost of blindness. Cost analysis enables incorporation of these aspects of treatment with the quality of life data to provide a better comparison of treatments over time. This analysis has provided a method for individual analysis and therefore can provide the structure for resource allocation. Financial Disclosure(s) The authors have no proprietary or commercial interest in any materials discussed in this article.</description><identifier>ISSN: 0161-6420</identifier><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/j.ophtha.2008.07.018</identifier><identifier>PMID: 18930556</identifier><identifier>CODEN: OPHTDG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Angiogenesis Inhibitors - economics ; Biological and medical sciences ; Choroidal Neovascularization - economics ; Choroidal Neovascularization - etiology ; Choroidal Neovascularization - physiopathology ; Computer Simulation ; Cost of Illness ; Cost-Benefit Analysis ; Decision Trees ; Humans ; Macular Degeneration - complications ; Macular Degeneration - economics ; Macular Degeneration - physiopathology ; Medical sciences ; Miscellaneous ; Models, Economic ; Ophthalmology ; Photochemotherapy - economics ; Quality of Life ; Quality-Adjusted Life Years ; Randomized Controlled Trials as Topic ; Retinopathies ; Visual Acuity</subject><ispartof>Ophthalmology (Rochester, Minn.), 2008-12, Vol.115 (12), p.2192-2198</ispartof><rights>American Academy of Ophthalmology</rights><rights>2008 American Academy of Ophthalmology</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c542t-73d970378e2f1ef9a6806553f1e300aad53c9ad93764565e0474581d8b5906433</citedby><cites>FETCH-LOGICAL-c542t-73d970378e2f1ef9a6806553f1e300aad53c9ad93764565e0474581d8b5906433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ophtha.2008.07.018$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20943296$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18930556$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fletcher, E.C., MRCOphth</creatorcontrib><creatorcontrib>Lade, R.J., PhD, MBA</creatorcontrib><creatorcontrib>Adewoyin, T., MRCOphth</creatorcontrib><creatorcontrib>Chong, N.V., FRCOphth, MD</creatorcontrib><title>Computerized Model of Cost-Utility Analysis for Treatment of Age-Related Macular Degeneration</title><title>Ophthalmology (Rochester, Minn.)</title><addtitle>Ophthalmology</addtitle><description>Purpose To present a computerized model assessing individualized cost utility for current treatments for neovascular age-related macular degeneration (AMD) to enhance discussion regarding treatment options. Design Case- and eye-specific cost-utility analysis using individual case scenarios. Participants Visual acuity data from published randomized controlled trials are incorporated into this analysis. Methods Computerized model (Microsoft Visual Basic 6.0 programming) to establish preference-based cost-utility analysis in association with individual cost of treatment and blindness for neovascular AMD for both the better and worst seeing eye, with extrapolation of results over a 5-year term. Main Outcome Measures Cost per quality-adjusted life-year (QALY) and cost per QALY gained for comparison of treatments for specific visual acuities. Results All treatments show an increase in utility in comparison with best supportive care (BSC) if the better-seeing eye is treated. Ranibizumab, using the Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularisation (CNV) with or without Classic CNV Secondary to AMD (PIER) regimen, is the most cost effective at $626 938 per QALY gained for treatment of the better seeing eye. To increase utility value when treating the worst seeing eye, the vision must improve to such a degree that it becomes the better seeing eye. This level of improvement is only possible if there is <9 letters difference between the 2 eyes and treated with ranibizumab. Over 5 years, increasing influence from the cost of blindness results in increasing costs for those treatments unable to stabilize vision. Within 5 years, the cost per QALY for the BSC is greater than all treatments except monthly ranibizumab injections. Conclusions Assessment of cost of treatment incorporates both effectiveness of treatment, cost of treatment, and cost of blindness. Cost analysis enables incorporation of these aspects of treatment with the quality of life data to provide a better comparison of treatments over time. This analysis has provided a method for individual analysis and therefore can provide the structure for resource allocation. Financial Disclosure(s) The authors have no proprietary or commercial interest in any materials discussed in this article.</description><subject>Angiogenesis Inhibitors - economics</subject><subject>Biological and medical sciences</subject><subject>Choroidal Neovascularization - economics</subject><subject>Choroidal Neovascularization - etiology</subject><subject>Choroidal Neovascularization - physiopathology</subject><subject>Computer Simulation</subject><subject>Cost of Illness</subject><subject>Cost-Benefit Analysis</subject><subject>Decision Trees</subject><subject>Humans</subject><subject>Macular Degeneration - complications</subject><subject>Macular Degeneration - economics</subject><subject>Macular Degeneration - physiopathology</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Models, Economic</subject><subject>Ophthalmology</subject><subject>Photochemotherapy - economics</subject><subject>Quality of Life</subject><subject>Quality-Adjusted Life Years</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Retinopathies</subject><subject>Visual Acuity</subject><issn>0161-6420</issn><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkl1rFDEUhoModlv9ByJzo3cznky-b4Rl1SpUBG0vJaSZM23W2cmaZIT11zvDLgre9CoEnvdNeM4h5AWFhgKVb7ZN3N-Xe9e0ALoB1QDVj8iKCm5qrih7TFYzRmvJWzgj5zlvAUBKxp-SM6oNAyHkinzfxN1-KpjCb-yqz7HDoYp9tYm51DclDKEcqvXohkMOuepjqq4TurLDsSzY-g7rrzi4smSdnwaXqnd4hyMmV0Icn5EnvRsyPj-dF-Tmw_vrzcf66svlp836qvaCt6VWrDMKmNLY9hR746QGKQSbLwzAuU4wb1xnmJJcSIHAFReadvpWGJCcsQvy-ti7T_HnhLnYXcgeh8GNGKdspdGCKeAPgi1Q0EqaGeRH0KeYc8Le7lPYuXSwFOzi327t0b9d_FtQdvY_x16e-qfbHXb_QifhM_DqBLjs3dAnN_qQ_3ItGM5as3BvjxzO2n4FTDb7gKPHLiT0xXYxPPST_wv8EMYwv_kDD5i3cUrzWLOlNrcW7LdlV5ZVAQ2gpFLsD3ueuOA</recordid><startdate>20081201</startdate><enddate>20081201</enddate><creator>Fletcher, E.C., MRCOphth</creator><creator>Lade, R.J., PhD, MBA</creator><creator>Adewoyin, T., MRCOphth</creator><creator>Chong, N.V., FRCOphth, MD</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20081201</creationdate><title>Computerized Model of Cost-Utility Analysis for Treatment of Age-Related Macular Degeneration</title><author>Fletcher, E.C., MRCOphth ; Lade, R.J., PhD, MBA ; Adewoyin, T., MRCOphth ; Chong, N.V., FRCOphth, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c542t-73d970378e2f1ef9a6806553f1e300aad53c9ad93764565e0474581d8b5906433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Angiogenesis Inhibitors - economics</topic><topic>Biological and medical sciences</topic><topic>Choroidal Neovascularization - economics</topic><topic>Choroidal Neovascularization - etiology</topic><topic>Choroidal Neovascularization - physiopathology</topic><topic>Computer Simulation</topic><topic>Cost of Illness</topic><topic>Cost-Benefit Analysis</topic><topic>Decision Trees</topic><topic>Humans</topic><topic>Macular Degeneration - complications</topic><topic>Macular Degeneration - economics</topic><topic>Macular Degeneration - physiopathology</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Models, Economic</topic><topic>Ophthalmology</topic><topic>Photochemotherapy - economics</topic><topic>Quality of Life</topic><topic>Quality-Adjusted Life Years</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Retinopathies</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fletcher, E.C., MRCOphth</creatorcontrib><creatorcontrib>Lade, R.J., PhD, MBA</creatorcontrib><creatorcontrib>Adewoyin, T., MRCOphth</creatorcontrib><creatorcontrib>Chong, N.V., FRCOphth, MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology (Rochester, Minn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fletcher, E.C., MRCOphth</au><au>Lade, R.J., PhD, MBA</au><au>Adewoyin, T., MRCOphth</au><au>Chong, N.V., FRCOphth, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Computerized Model of Cost-Utility Analysis for Treatment of Age-Related Macular Degeneration</atitle><jtitle>Ophthalmology (Rochester, Minn.)</jtitle><addtitle>Ophthalmology</addtitle><date>2008-12-01</date><risdate>2008</risdate><volume>115</volume><issue>12</issue><spage>2192</spage><epage>2198</epage><pages>2192-2198</pages><issn>0161-6420</issn><eissn>1549-4713</eissn><coden>OPHTDG</coden><abstract>Purpose To present a computerized model assessing individualized cost utility for current treatments for neovascular age-related macular degeneration (AMD) to enhance discussion regarding treatment options. Design Case- and eye-specific cost-utility analysis using individual case scenarios. Participants Visual acuity data from published randomized controlled trials are incorporated into this analysis. Methods Computerized model (Microsoft Visual Basic 6.0 programming) to establish preference-based cost-utility analysis in association with individual cost of treatment and blindness for neovascular AMD for both the better and worst seeing eye, with extrapolation of results over a 5-year term. Main Outcome Measures Cost per quality-adjusted life-year (QALY) and cost per QALY gained for comparison of treatments for specific visual acuities. Results All treatments show an increase in utility in comparison with best supportive care (BSC) if the better-seeing eye is treated. Ranibizumab, using the Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularisation (CNV) with or without Classic CNV Secondary to AMD (PIER) regimen, is the most cost effective at $626 938 per QALY gained for treatment of the better seeing eye. To increase utility value when treating the worst seeing eye, the vision must improve to such a degree that it becomes the better seeing eye. This level of improvement is only possible if there is <9 letters difference between the 2 eyes and treated with ranibizumab. Over 5 years, increasing influence from the cost of blindness results in increasing costs for those treatments unable to stabilize vision. Within 5 years, the cost per QALY for the BSC is greater than all treatments except monthly ranibizumab injections. Conclusions Assessment of cost of treatment incorporates both effectiveness of treatment, cost of treatment, and cost of blindness. Cost analysis enables incorporation of these aspects of treatment with the quality of life data to provide a better comparison of treatments over time. This analysis has provided a method for individual analysis and therefore can provide the structure for resource allocation. Financial Disclosure(s) The authors have no proprietary or commercial interest in any materials discussed in this article.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>18930556</pmid><doi>10.1016/j.ophtha.2008.07.018</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-6420 |
| ispartof | Ophthalmology (Rochester, Minn.), 2008-12, Vol.115 (12), p.2192-2198 |
| issn | 0161-6420 1549-4713 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69853704 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Angiogenesis Inhibitors - economics Biological and medical sciences Choroidal Neovascularization - economics Choroidal Neovascularization - etiology Choroidal Neovascularization - physiopathology Computer Simulation Cost of Illness Cost-Benefit Analysis Decision Trees Humans Macular Degeneration - complications Macular Degeneration - economics Macular Degeneration - physiopathology Medical sciences Miscellaneous Models, Economic Ophthalmology Photochemotherapy - economics Quality of Life Quality-Adjusted Life Years Randomized Controlled Trials as Topic Retinopathies Visual Acuity |
| title | Computerized Model of Cost-Utility Analysis for Treatment of Age-Related Macular Degeneration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T09%3A33%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Computerized%20Model%20of%20Cost-Utility%20Analysis%20for%20Treatment%20of%20Age-Related%20Macular%20Degeneration&rft.jtitle=Ophthalmology%20(Rochester,%20Minn.)&rft.au=Fletcher,%20E.C.,%20MRCOphth&rft.date=2008-12-01&rft.volume=115&rft.issue=12&rft.spage=2192&rft.epage=2198&rft.pages=2192-2198&rft.issn=0161-6420&rft.eissn=1549-4713&rft.coden=OPHTDG&rft_id=info:doi/10.1016/j.ophtha.2008.07.018&rft_dat=%3Cproquest_cross%3E69853704%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20108769&rft_id=info:pmid/18930556&rft_els_id=S0161642008007677&rfr_iscdi=true |